Networking +
Policy +
Member
Career
Choose
Colorado BioScience Association is thrilled to announce the full slate of companies selected to present at the 2026 Rocky Mountain Life Sciences Investor and Partnering Conference in Vail September 30-October 2.
Close to 50 vetted companies will present investment and partnership opportunities across biotech, pharma, medical device, diagnostics, digital health, and animal health. From emerging startups to Series A and B opportunities, this year’s lineup showcases the breadth of health innovation across Colorado and the Rocky Mountain West, with companies advancing platforms, pipelines, devices, diagnostics, and technologies designed to save and change lives.
Meet the Presenting Companies
Biotech + Pharma: Pre-Seed and Seed
Funding Sought: $2M Pre-Seed
At Andon Bio, we're making protein production predictable. We're the first to measure the cell's charged-tRNA supply, the resource protein synthesis depends on but that no existing tool can see. Our data lets ML models learn what makes a sequence express well, and how to redesign the ones that don't. We are bringing this missing measurement to the $50B+ protein production market.
Recent News:
Won Alnylam's Delivery Frontier Award as a Nucleate 2026 GVA Finalist
Awarded $150K Colorado OEDIT Grant to Advance the aa-tRNA-seq Method Behind Andon Bio
Funding Sought: $5M Seed
GenesisTissue Inc. is a biotechnology company using 3D printing to develop the next generation of personalized surgical solutions for soft tissue – starting with the breast. Our platform includes Regenerative Breast Tissue (RBT), a biodegradable scaffold that supports soft tissue regeneration, and OnPlants™, a patient-specific wearable that allows patients and surgeons to evaluate aesthetic outcomes before surgery. GenesisTissue Inc. is advancing a patient-centered approach to breast surgery by integrating 3D printing, biomaterials science, and personalized design.
Recent News:
Funding Sought: $3M Seed
Illumen Therapeutics, a University of Colorado spinout, is pursuing a novel therapeutic strategy to treat aggressive cancers, such as colorectal and pancreatic cancers, by restoring functional p53 through inhibiting the enzyme PARN. This breakthrough in oncology drug development avoids the historical problems exhibited with MDM2 inhibitors.
Recent News:
Funding Sought: $5M Seed
Intero Biosystems has developed the first induced pluripotent stem cell (iPSC)-derived Human Intestinal Organoid to contain the major cell types of the human intestine mimicking the organ’s spatial organization and function. GastroScreen can be used in preclinical assays, disease modeling, toxicity testing, and in functional tests to predict how drugs will behave in humans, mitigating risk, saving money, and identifying safer more effective compounds.
Recent News:
Funding Sought: $3M Seed
Parley Neurotech is a clinical-stage University of Colorado Anschutz spinout developing LOOT, a combination therapy pairing clemastine fumarate with proprietary engineered acoustic stimulation to treat age-related central auditory processing disorder (CAPD), a modifiable dementia risk factor. By restoring the ability to hear speech in noise, Parley aims to slow cognitive decline. Its Phase I/IIa trial enrolled its first volunteer in April 2026.
Recent News:
Developed Treatment for Form of Age-Related Central Auditory Processing Disorder
Funding Sought: $10M Seed
Pearl Scientific is developing a first-in-class therapeutic platform targeting SEMA7A, a driver of therapy resistance, metastatic recurrence, and breast cancer–related mortality. Extensive preclinical studies and analyses of patient datasets demonstrate that SEMA7A functions both as a critical disease mediator and a biomarker that defines high-risk breast cancer subtypes.
Recent News:
Funding Sought: $2.5M Seed
Pionarus Bio is a pharmaceutical company developing cannabinoid-inspired therapeutics for bone health, headquartered at the Fitzsimmons Innovation Campus at CU Anschutz in Aurora, Colorado. Our lead candidate, PIO-001, is a selective CB2 receptor agonist engineered for enhanced metabolic stability through strategic molecular design, targeting the well-validated role of the endocannabinoid system in regulating bone remodeling. PIO-001 addresses both the traditional osteoporosis population and GLP-1 associated bone loss, a rapidly growing indication with no approved therapies.
Funding Sought: $4M Seed
Renovare Therapeutics is a biotechnology company developing a pipeline of regenerative therapies for osteoarthritis (OA), a disease impacting 500 million patients globally with no disease-modifying treatments available. Our technology spans advanced particle drug delivery, regenerative biomaterials, and engineered gene therapy, allowing us to address the full disease spectrum. Backed by up to $33.5M in non-dilutive funding awarded by ARPA-H to our partner, University of Colorado Boulder, we are advancing two lead candidates into IND-enabling and Phase 1 studies by 2028. Renovare Therapeutics launched from stealth in April led by a founding team that unites deep commercial experience with world-class scientific leadership from CU Boulder, CU Anschutz, and Colorado State University.
Recent News:
Funding Sought: $6M Seed
Funding Sought: $2M Pre-Seed
Wave Bye provides a proactive solution for menstrual pain and heavy bleeding by targeting the biological pathway that causes symptoms before they begin. Instead of treating cramps after they start, the product is designed to be taken shortly before menstruation to interrupt the prostaglandin cascade responsible for both pain and excess bleeding.
Recent News:
Received Investment at Emmeline Ventures' Culture Shifting Deal-Making Summit
Biotech + Pharma: Series A and B
Funding Sought: $14M Series A
Numiera Therapeutics is developing small-molecule drugs for oncology indications, by targeting a critical vulnerability in cancer cell metabolism. Our orphan-designated lead asset has Phase I clinical data with a promising safety profile, plus independently replicated preclinical efficacy data. Our next step is a dose-escalation and window-of-opportunity study conducted with our world-class clinical neuro oncology partners. We are currently raising a $14M Series A round to complete this work.
Recent News:
Funding Sought: $5M Series A
At PhotonPharma, every patient’s tumor becomes a part of their cure. PhotonPharma utilizes patented technology to create antigen presenting tumor cells for immune activation and targeted tumor destruction. The InnocellTM vaccine is easily manufactured from patient tumor to deliver a personalized vaccine specific for each patient. The company has recently initiated human clinical evaluation under an FDA cleared IND in women with relapsed ovarian cancer. The approach should be applicable to any solid organ tumor where tumor tissue is accessible by surgical excision or biopsy.
Recent News:
Received U.S. Patent for Innovative Cancer Immunotherapy
Presented Novel Autologous Treatment Platform at Premier Cancer Immunotherapy Conference
Funding Sought: $8M Series A-2
Rebel Medicine is a clinical-stage company developing innovative long-acting injectable drug delivery technologies that sustain release from days to months. Our lead asset, ALX006, is a long-acting local anesthetic delivering 3-4 days of opioid-sparing postoperative analgesia from a single injection, currently in a first-in-human Phase 2 trial. Built on our proprietary lipid platform, that provides tunable drug release for small molecules, peptides, and proteins from days to months.
Recent News:
Awarded NSF SBIR Phase 2b and NIH SBIR Phase 1 Grants
Published Data from Alevatrix™ Large Animal Pre-Clinical Studies
Funding Sought: $23M Series A
SiVEC Biotech is advancing first-in-class therapies by harnessing their groundbreaking BactPac™ drug delivery platform. BactPac uses the power of engineered bacteria to overcome the biggest hurdles in developing and commercializing biologics, achieving safe, targeted delivery with the added advantage of simple, scalable manufacturing. BactPac delivers a diverse array of biologics, including mRNA, siRNA, proteins, and CRISPR gene editors, with precision and safety that surpass traditional delivery methods.
Recent News:
Announced Partnership with RheumaGen to Advance In Vivo Gene-Editing Therapies
Think Bioscience is a privately held small molecule drug discovery company based in Boulder, Colorado, focused on developing therapeutics against targets that have historically been considered "undruggable". The company's team combines expertise in synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry to launch first-in-class program for diseases with high unmet need.
Recent News:
VitriVax is a Boulder, Colorado-based biotechnology company advancing the ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) platform, a novel technology designed to overcome key challenges in vaccine delivery. ALTA® combines thermostabilization and controlled-release technologies to protect vaccine components from degradation and enable programmable antigen release over time. The platform has the potential to eliminate cold-chain requirements, reduce multi-dose vaccination schedules to a single administration, and support the co-formulation of multiple vaccine components in a single product. By addressing critical barriers to vaccination, VitriVax aims to improve vaccine accessibility, patient adherence, and global health outcomes.
Recent News:
Raised $17.25 Million Series B Financing to Advance Vaccine Formulation Platform
Awarded $9.9M Grant to Enable Scaling Up of Clinical Manufacturing
Medtech, Diagnostics, + Digital Health: Pre-Seed + Seed
Funding Sought: $3M Seed
Biota delivers a fully integrated solution to modernize PFAS testing through two complementary products—combining breakthrough lab efficiency with real-time field intelligence. Biota is not just improving PFAS testing—we are rebuilding the infrastructure of environmental diagnostics to match the speed, scale, and impact required to protect human health.
Recent News:
Awarded $250k Colorado OEDIT Advanced Industries Grant
Awarded $305k National Institute of Environmental Health Sciences SBIR Phase I Grant
Funding Sought: $3M Seed
Decorum Medical Innovations is transforming the multi-billion-dollar advanced airway market with patented technology that automates the cleaning and maintenance of tracheostomy and airway tubes. Our AutoTrach® platform addresses a longstanding unmet clinical need, reducing risk, labor, and cost while improving patient outcomes and independence. By fundamentally reimagining airway care, Decorum is creating a new clinical standard and a scalable platform opportunity in respiratory medicine.
Recent News:
Funding Sought: $3M Seed
Surgeons cannot fix what they cannot see. Emet Surgical's ESP is an AI-powered real-time copilot for minimally invasive surgery, built on NSF-funded University of Minnesota research. Scope and robot agnostic, ESP requires no training or workflow changes.
Clinical studies launching this year on ESP’s use in endometriosis surgery will drive regulatory filings while generating real-world evidence of ESP's financial and patient care impact.
Recent News:
Named Finalist in Intel – Startup Nation Central Edge AI Challenge
Featured in BioScience Colorado Magazine: Smarter Surgery with a Survivor's Perspective
Funding Sought: $1.25M Seed
Entirely Well is a biotech/medical device company on a mission to develop preventive care and make it accessible to everyone. We believe true health goes beyond treating symptoms — empowering people to take ownership of their health before problems arise starting with yeast infections and bacterial vaginosis, which affects 46+ million people per year in the United States.
Recent News:
Funding Sought: $5M Seed
ExOcular is revolutionizing the management of severe eye diseases. We're developing a portfolio of blood-based multiplex tests built on exosome-based, disease-specific biomarkers. These tests provide early, and actionable insights, paving the way for personalized and transformative patient care. We empower physicians with unparalleled insights to deliver earlier, more effective treatments.
Recent News:
Joined Wyss Institute at Harvard University Diagnostic Accelerator
Flari is building a breath analysis platform based on cutting-edge quantum sensing technologies that represent a new category of analytical methods for studying molecular biology and metabolomics. This platform can support R&D as well as test development and implementation. It promises to broaden testing options for a wide variety of diseases and monitoring needs.
Recent News:
Funding Sought: $1M Seed
Flourish Medical is a women’s health medical device company developing the first single-use, no-sizing-needed pessary for stress urinary incontinence. Designed for discreet, on-demand use without prescription, fitting appointments, or cleaning, it provides immediate symptom relief and expands access to care. The company is advancing FDA 510(k) clearance and preparing for U.S. commercial launch.
Recent News:
Awarded Colorado OEDIT Advanced Industries Accelerator Grant
Funding Sought: $1.5M Seed
Jura Health is pioneering patient-centered solutions that combine genomic diagnostics, care navigation, and social determinant support for patients with rare and complex conditions that do not have access to leading medical and research institutions. By shortening the 6-year diagnostic odyssey to 5 weeks, we save healthcare costs ranging between $80,000 to over $500,000 per patient and improve medical management in up to 70% of cases.
Recent News:
Funding Sought: $2M Seed Extension
Myomar Molecular is transforming muscle health monitoring through the world's first urine-based molecular biomarker platform for the early detection and management of muscle loss, sarcopenia, frailty, and metabolic disorders. The company's proprietary technology provides clinicians and patients with a simple, non-invasive alternative to costly imaging-based assessments, enabling earlier intervention, personalized care, and improved outcomes for aging populations, chronic disease patients, athletes, and users of weight management therapies.
Recent News:
Closed $3.5M Round and Expands to U.S. and Asia (Entrevestor)
Took Top Accolades at Venture North PITCH 2025 (Northern Ontario Business)
NavaPath 
Funding Sought: $1.5M Seed
NavaPath develops point-of-care cervical cancer screening tools to facilitate timely medical intervention. We provide cost-effective testing to scale cervical cancer screening to all women, regardless of location or socioeconomic status. By deploying these decentralized solutions, we improve clinical outcomes through early detection.
Funding Sought: $3M Seed
Omedus created Triage360, a dual-use autonomous monitoring platform built to improve casualty triage in defense settings and continuous patient surveillance in hospitals and rural health systems. Its wearable Beacon captures real-time physiologic data, helping clinicians identify deterioration earlier, reduce manual spot checks, support staffing-constrained teams, and extend monitoring beyond the bedside to lower-resource and remote care environments.
SusMer is developing next-generation bioresorbable polymer technology to enable safer, higher-performing medical devices. Our proprietary manufacturing platform produces ultra-high-purity poly-4-hydroxybutyrate (P4HB) with tunable molecular weights for applications including surgical mesh, sutures, cardiovascular devices, and drug delivery. We partner with leading medical device companies to accelerate commercialization of advanced biomaterials.
Recent News:
Funding Sought: $5M Seed
TissueForm has developed Allovia™, a flowable implant for repairing cartilage defects that provides immediate structural support. Made from natural materials derived from human cartilage tissue, Allovia is an off-the-shelf, resorbable implant designed to support the body's natural healing response in the knee. Our goal is to make joint replacement the last resort—not the only hope.
Recent News:
Funding Sought: $2.75M Seed
Transformative Biotech is transforming PCR testing for infectious diseases with patented direct-to-PCR platform technologies. Clinically validated on more than 590,000 patient samples, our platform enables rapid, accurate, and affordable molecular testing. @ANYWHERE™, our smartphone-powered handheld PCR platform in development, is designed to expand access to testing, accelerate treatment, and reduce the spread of infectious diseases worldwide, ultimately saving lives.
Recent News:
Founded in 2022, Vega Surgical is a medical technology company dedicated to advancing neurosurgical care. Headquartered in Aurora, Colorado, our organization was born from a direct clinical need identified by neurosurgeons Joshua Seinfeld, M.D., and Zach Folzenlogen, M.D., during their collaborative work at CU Medicine. By bridging the gap between clinical practice and advanced engineering—led by CTO Mike Bojanowski—we develop solutions for complex neurosurgical challenges.
Funding Sought: $3M Seed
Vital Foams is raising a seed round to address a critical gap in trauma care: immediate control of bleeding and polymicrobial contamination before patients reach definitive treatment. The company is developing a defensible wound-care platform combining a proprietary medical foam with a ruggedized in situ generator for military, EMS, and civilian trauma settings. Backed by non-dilutive funding from the DoW, Orthopaedic Trauma Association, and private foundations, Vital Foams is advancing toward preclinical validation, regulatory readiness, and commercialization.
Recent News:
Awarded $1.5M in Grant Funding for CSU Antibiotic Wound Foam Research
Funding Sought: $5M Seed
VitaWave Tech is developing eBP, a clinical-grade, in-ear blood pressure monitor that delivers FDA AAMI-compliant accuracy with the ease of an earbud. Targeting hypertension, preeclampsia, and chronic kidney disease patients, eBP enables remote patient monitoring through a connected mobile app and provider portal with EHR integration. VitaWave holds an exclusive license to US Patent #12,521,027 via the University of Colorado and is advancing toward FDA 510(k) clearance and clinical pilot deployment in 2027.
Recent News:
Won Second Prize at the Purdue Innovates New Venture Challenge 2026
Medtech, Diagnostics, + Digital Health: Series A + B
Funding Sought: $5M Series A
ActivArmor is revolutionizing the orthopedic fracture care market with next-gen, 3D-printed custom casts, fabricated at the point-of-care. With over 7,500 patients successfully treated so far, our turnkey digital system gives physicians the ability to easily custom design and fabricate bespoke casts that are waterproof, breathable, sanitizable, adjustable for swelling, and recyclable, providing unmatched patient healing outcomes, comfort, hygiene, and freedom during recovery.
Recent News:
Awarded $1.2M DHA SBIR Phase II Contract
Continued ActivArmor Expansion Includes Strategic Partnership with 3D Printing Pioneer in Singapore
AOA Dx is transforming early cancer detection with its proprietary platform, a first-of-its-kind, multi-omics liquid biopsy that integrates lipids, metabolites, proteins and clinical data using advanced machine learning. The company’s lead test, AKRIVIS GD™, is designed to detect ovarian cancer early in symptomatic women, addressing a critical diagnostic gap in one of the deadliest cancers affecting women. In 2026, the company released a first-ever comprehensive women's health exit analysis, revealing $100B+ in realized value over 25 years.
Recent News:
Enrolled First Patient in APEX Study, Advancing Proprietary Biobank and Clinical Infrastructure
Funding Sought: $2M Series A
Burst Diagnostics is an early-stage diagnostics company translating laboratory-grade immunoassays into rapid, cost-effective formats for use in point-of-need settings. Its proprietary Capillary Driven Immunoassay (CaDI) platform delivers ten-minute quantitative results through an easy-to-use format, supporting both Burst-branded products and custom assay solutions. BurstDX will begin with the launch of a testosterone test before expanding to additional hormone targets for both men and women long-term. The platform enables detection across a broad range of targets and sample types in clinical and non-clinical applications, including food safety, veterinary diagnostics, wellness, environmental monitoring, and beyond.
Recent News:
Secured NIH Funding to Advance At-Home Diagnostics for Perimenopause
Funding Sought: $10M Series A
cliexa is the intelligence layer where clinical science, payer logic, and patient reality meet in real time. Health systems use it to ensure evidence-based care gets delivered and paid. Life sciences partners — including global pharma and the American College of Cardiology — use it to embed validated clinical reasoning directly into care workflows. One platform, a decade in production — from community hospitals to federal health systems.
Recent News:
Funding Sought: $8M Series A
Eye to Eye Telehealth is a glaucoma-focused medical device and digital health company modernizing care through connected home-use tonometry and data analytics. E2E’s platform helps patients measure intraocular pressure outside the clinic and gives clinicians contextual insights for timely, personalized treatment decisions.
Funding Sought: $10M Series A
GelSana is developing innovative wound dressings with the potential to address the major challenges of the wound healing cascade by reducing inflammation, repelling bacteria, balancing moisture, and providing a protective barrier, all in a single, shelf-stable wound dressing.
Recent News:
Launched CleraFlex, the World’s First Stretchable Wound Dressing
Funding Sought: $40M
HepQuant’s mission and vision is to transform the clinical management of patients with chronic liver disease through precision diagnostics of liver health. Our testing platform includes HepQuant DuO®, currently marketed for clinical practice, and the recently FDA approved HepQuant SHUNT® Liver Diagnostic Test. The laboratory, regulatory, clinical, commercial, and financial foundations have been laid for market adoption, reimbursement, growth, and partnering. Learn more at HepQuant.com.
Recent News:
Innovative Midfoot Solutions (IMS)
Funding Sought: $6M
Funding Sought: $5M
Lasa Health is an AI clinical decision support company focused on closing the diagnostic gap for chronic pelvic pain conditions. Our EHR-embedded decision support tool, LasaCDS, screens for 20+ underdiagnosed conditions and delivers actionable differential diagnoses at the point of care. Developed in collaboration with Mayo Clinic and trained on 10M+ health records, LasaCDS is currently being piloted at Mayo Clinic Arizona. Lasa Health is supported by NSF SBIR, ARPA-H, and Colorado OEDIT.
Recent News:
Named Subawardee on $3M ARPA-H Sprint for Women's Health project
Lazzaro Medical addresses the lack of effective, standardized surgical solutions for patients suffering from expiratory central airway collapse (ECAC), including tracheobronchomalacia (TBM). Lazzaro Medical has developed the Lazzaro Medical Scaffold System ™, a first-of-its-kind, anatomically optimized implant designed specifically for reinforcement of the central airway during tracheobronchoplasty. Unlike generic mesh, the system is engineered for airway anatomy, enabling improved visualization, controlled tensioning, and more consistent suturing during robotic and open procedures.
Recent News:
Received FDA Breakthrough Device Designation for the LM Scaffold System
Lazzaro Medical wins $2.4M SBIR grant from National Institutes of Health
Funding Sought: $20M Series A
YoungHeartValve is a preclinical MedTech company developing a balloon-expandable transcatheter aortic valve replacement (TAVR) with the first biopolymeric leaflet material, designed to mitigate the risks of long-term thrombosis, calcification and structural valve degeneration at a scalable cost. Our market-disruptive, durable biopolymeric technology is poised to set a new standard for the growing market of younger low-risk heart valve patients. The leaflets integrate the engineering plastic, polyethylene with the biopolymer, hyaluronic acid, at the molecular level.
Recent News:
Colorado Success Stories
Meet public and VC-backed companies that have grown rapidly in Colorado and raised significant capital.
Ambrosia Biosciences accelerated from stealth to a $100M Series B in less than 18 months. The company launched with a team of world-class medicinal chemists from Array Biopharma, which was acquired by Pfizer in 2019 for $11.8 billion in cash, the largest acquisition of a venture-backed life sciences company in the history of Colorado. Ambrosia, a privately held drug discovery company, is developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
Recent News:
Announced $25M Series A Financing, Including Strategic Investment by Merck
Biodesix (NASDAQ: BDSX)
Biodesix recently celebrated the fifth anniversary of its IPO and announced continued progress toward profitability. Recognized nationally and in Colorado for its executive leadership and as a top workplace, Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. To deliver on the company’s mission to transform patient care and improve outcomes through personalized diagnostics, Biodesix provides advanced diagnostic tests and custom development services.
Recent News:
Announced First Quarter 2026 Results: Delivered $25.6M in Revenue Representing 42% Growth in Q1 2026
Recognized as a USA TODAY Top Workplace for Third Consecutive Year
Celebrated 5 Year IPO Anniversary at Nasdaq Closing Bell Ceremony
The conference includes a focus on women’s health and quantum-enabled companies. Those companies are identified with the following symbols:
Women’s Health
Quantum Enabled
Meet Health Innovators Developing Emerging Breakthroughs: Innosphere Showcase Companies
The Rocky Mountain Life Sciences Investor & Partnering Conference is pleased to feature companies from the Innosphere Life Sciences Incubator in a dedicated tabletop showcase of emerging technologies. Rather than formal presentations or investor pitches, these companies will engage directly with attendees through interactive demos highlighting innovative life sciences concepts, early-stage discoveries, and technologies still in development. This Colorado-born launchpad for pioneering health innovation companies offers an unprecedented opportunity for startups to catapult their innovative life sciences concepts into market-ready solutions. Originally launched with support from Colorado's Office of Economic Development and International Trade in partnership with Colorado BioScience Association and Colorado BioScience Institute, the program has expanded to support promising startups in eight states, in partnership with eleven R1 Universities and three state bioscience associations with federal grant funding.
Momentum Snapshot: Successes Achieved by 2022 and 2024 Presenting Companies
